Abbvie's strategy has focused on delivering strong financial results, advancing and investing in its pipeline, and ensuring a strong, sustainable growth business over the long term. The company intends to continue to advance its mission by expanding operating margins and investing in its pipeline in support of opportunities in immunology, oncology, virology, and neurology. Abbvie's financial performance in 2016 included delivering diluted earnings per share of $3.63, reflecting the impact of its operational efficiency and strategic resource allocation. The company generated cash flows from operations of $7.0 billion, which Abbvie utilized to enhance its pipeline through licensing and collaboration activities, demonstrating its capability to mobilize and deploy IT-based resources in combination with other capabilities. Abbvie's commitment to research and innovation is underscored by its pipeline of more than 50 compounds or indications in clinical development, which is critical for maintaining competitive advantage in the biopharmaceutical industry. The company’s focus on operational flexibility and efficiency is evident in its productivity initiatives across supply chain and manufacturing processes, aimed at optimizing costs and enhancing performance metrics. Abbvie's investments in technology infrastructure and digital transformation are integral to its strategic objectives, enabling the company to respond effectively to market dynamics and consumer demands. The company also emphasizes the importance of information management capability, which encompasses the ability to provide data and information to users with appropriate levels of accuracy, timeliness, reliability, and security. This capability is vital for supporting business strategies and enhancing organizational effectiveness. Abbvie's strategic decisions regarding acquisitions, such as the purchase of Stemcentrx, reflect its approach to leveraging strategic resources and enhancing its technology portfolio to drive innovation and business transformation. The company’s financial activities, including significant investments in research and development, highlight its commitment to advancing its capabilities in the biopharmaceutical sector. Abbvie's operational strategies are designed to ensure that its IT capabilities evolve in scope to encompass the coordination of its assets and internal processes, thereby enhancing its market responsiveness and overall firm performance. The company's focus on building strong external relationships and fostering innovation partnerships is essential for navigating regulatory contexts and achieving long-term business value. Abbvie's ability to integrate technology capabilities with its organizational goals is a key factor in maintaining its competitive positioning and driving performance improvement across its business processes.